Pharmaceutical

Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Takeda Pharmaceutical Co. Ltd.August 28, 20264

Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

About this update from Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd. (4502) Press Release View Attachment

View stock analysis, news, and events for Takeda Pharmaceutical Co. Ltd.

More from Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical : Announces Planned Retirement of President of Research & Development Andy Plump

September 10, 2026

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narco...

September 9, 2026

All Takeda Pharmaceutical Co. Ltd. news →